User: Guest  Login
Title:

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.

Document type:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Article
Author(s):
Hess, G; Keller, U; Scholz, C W; Witzens-Harig, M; Atta, J; Buske, C; Kirschey, S; Ruckes, C; Medler, C; van Oordt, C; Klapper, W; Theobald, M; Dreyling, M
Abstract:
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number...     »
Journal title abbreviation:
Leukemia
Year:
2015
Journal volume:
29
Journal issue:
8
Pages contribution:
1695-701
Language:
eng
Fulltext / DOI:
doi:10.1038/leu.2015.60
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/25765545
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX